ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AEZ American Oil & Gas Common Stock

0.00
0.00 (0.00%)
Share Name Share Symbol Market Type
American Oil & Gas Common Stock NYSE:AEZ NYSE Ordinary Share
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.00 -

TRADE NEWS: Agilent Technologies Introduces OneSeq to Streamline Cytogenetic Research

25/02/2015 4:00pm

Business Wire


American Oil & Gas Common Stock (NYSE:AEZ)
Historical Stock Chart


From Jun 2019 to Jun 2024

Click Here for more American Oil & Gas Common Stock Charts.

Assay Allows Scientists to Identify Mutations and Copy Number Changes in a Single Reaction

Agilent Technologies Inc. (NYSE:A) today introduced OneSeq, the industry’s first all-in-one target enrichment product for next-generation sequencing. OneSeq is designed to detect and analyze copy number variations, loss of heterozygosity, and mutations in a single reaction for use in constitutional disease research.

Agilent is showcasing the new product at the annual Advances in Genome Biology and Technology (AGBT) conference in Marco Island, Florida, this week.

Powered by Agilent’s industry-leading SureSelect target-enrichment platform, the new OneSeq constitutional research panel will help laboratories involved in cytogenetic research save time gathering and analyzing complex, multifactorial data.

“OneSeq enables researchers to study both disease-associated targets and copy number variants at the same time,” said Alessandro Borsatti, a senior director of marketing at Agilent. “The all-in-one NGS assay—another industry first from the pioneers of target enrichment—provides more information than single molecular techniques, allowing scientists to streamline their workflow.”

Borsatti noted that researchers can easily combine OneSeq with Agilent’s free-of-charge SureCall software to integrate data analysis of copy number variations, single nucleotide polymorphisms, indels, and loss of heterozygosity.

“This combination offers the most cost-effective and streamlined method of studying multiple DNA changes associated with genetic disorders,” Borsatti said. “Whole genome sequencing and its associated data analysis are far more laborious and costly.”

In addition, Agilent’s online design application, SureDesign, enables researchers to customize OneSeq by adding any gene panel of interest to the CNV backbone to suit their needs.

About Agilent Technologies

Agilent Technologies Inc. (NYSE:A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenues of $4.0 billion in fiscal 2014. The company employs about 12,000 people worldwide. Information about Agilent is available at www.agilent.com.

NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at www.agilent.com/go/news.

for Agilent Technologies Inc.Jennifer Mann, +1 303-357-2391jmann@webershandwick.com

1 Year American Oil & Gas Common Stock Chart

1 Year American Oil & Gas Common Stock Chart

1 Month American Oil & Gas Common Stock Chart

1 Month American Oil & Gas Common Stock Chart